Brought to you by 
Amgen's BDNF to be delivered using Medtronic's Synchromed
13 Jul 1999
Executive Summary
Amgen and Medtronic have agreed to collaborate in research on the use of Medtronic's SynchroMed implantable drug infusion system to deliver brain-derived neurotrophic factor (BDNF) directly into cerebrospinal fluid.
Deal Industry
- Medical Devices
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
-
Medical Devices
- Implantable Devices
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Amgen's BDNF to be delivered using Medtronic's Synchromed
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice